136 related articles for article (PubMed ID: 2199892)
1. [Factors influencing leukemic transformation in myelodysplastic syndrome].
Borbényi Z; Varga G; Bérczi M; Gurzó M
Orv Hetil; 1990 Jun; 131(23):1231-6, 1239-40. PubMed ID: 2199892
[TBL] [Abstract][Full Text] [Related]
2. Transformation of myelodysplastic syndromes into acute myeloid leukemias.
Shi J; Shao ZH; Liu H; Bai J; Cao YR; He GS; Tu MF; Wang XL; Hao YS; Yang TY; Yang CL
Chin Med J (Engl); 2004 Jul; 117(7):963-7. PubMed ID: 15265365
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic and prognostic values of in vitro culture growth patterns of marrow granulocyte-macrophage progenitors in patients with myelodysplastic syndrome.
Shih LY; Chiu WF; Lee CT
Leukemia; 1991 Dec; 5(12):1092-8. PubMed ID: 1774958
[TBL] [Abstract][Full Text] [Related]
4. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.
Kröger N; Bornhäuser M; Ehninger G; Schwerdtfeger R; Biersack H; Sayer HG; Wandt H; Schäfer-Eckardt K; Beyer J; Kiehl M; Zander AR;
Ann Hematol; 2003 Jun; 82(6):336-42. PubMed ID: 12728337
[TBL] [Abstract][Full Text] [Related]
5. Low dose cytosine arabinoside therapy in myelodysplastic syndrome and acute myeloid leukemia.
Katayama N; Tanaka I; Minami N; Shirakawa S
Jpn J Clin Oncol; 1987 Jun; 17(2):117-21. PubMed ID: 3475489
[TBL] [Abstract][Full Text] [Related]
6. [Study on the transformation from myelodysplastic syndromes into acute leukemias].
Shi J; Shao Z; Liu H; Li K; Song L; Zhang Y; Zheng Y; Chen G; Chu Y; He H; Zhao M; He G; Feng B; Hao Y; Yang T; Yang C
Zhonghua Xue Ye Xue Za Zhi; 2001 Jul; 22(7):351-4. PubMed ID: 11877096
[TBL] [Abstract][Full Text] [Related]
7. Treatment with low-dose cytosine arabinoside followed by administration of macrophage colony-stimulating factor prolongs the survival of patients with RAEB, RAEB-T, or leukemic phase myelodysplastic syndrome: a pilot study.
Fukuhara T; Miyake T; Maekawa I; Kurosawa M; Suzuki S; Noto S; Mori A; Chiba K; Toyoshima T; Hirano T; Morioka M; Tsutsumi Y; Okabe M; Kakinoki Y
Int J Hematol; 2000 Jun; 71(4):366-71. PubMed ID: 10905057
[TBL] [Abstract][Full Text] [Related]
8. Therapy-related myelodysplastic syndrome with monosomy 5 after successful treatment of acute myeloid leukemia (M2).
Ogasawara T; Yasuyama M; Kawauchi K
Am J Hematol; 2005 Jun; 79(2):136-41. PubMed ID: 15929101
[TBL] [Abstract][Full Text] [Related]
9. Karyotype is prognostically more important than the FAB system's distinction between myelodysplastic syndrome and acute myelogenous leukemia.
Estey EH; Keating MJ; Dixon DO; Trujillo JM; McCredie KB; Freireich EJ
Hematol Pathol; 1987; 1(4):203-8. PubMed ID: 3504436
[TBL] [Abstract][Full Text] [Related]
10. Idarubicin and cytosine arabinoside in the induction and maintenance therapy of high-risk myelodysplastic syndromes.
Invernizzi R; Pecci A; Rossi G; Pelizzari AM; Giusto M; Tinelli C; Ascari E
Haematologica; 1997; 82(6):660-3. PubMed ID: 9499664
[TBL] [Abstract][Full Text] [Related]
11. Idarubicin and cytosine arabinoside in the induction and maintenance therapy of high-risk myelodysplastic syndromes.
Invernizzi R; Pecci A; Rossi G; Pelizzari AM; Giusto M; Tinelli C; Ascari E
Haematologica; 1997; 82(5 Suppl):9-12. PubMed ID: 9402747
[TBL] [Abstract][Full Text] [Related]
12. [Myelodysplastic syndrome--classification, prognosis and therapy].
Cermák J; Michalová K; Vítek A
Cas Lek Cesk; 2002 Sep; 141 Suppl():33-7. PubMed ID: 12428420
[TBL] [Abstract][Full Text] [Related]
13. Disappearing myelodysplastic syndrome-associated hemolytic anemia in leukemic transformation.
Tabata R; Tabata C; Omori K; Nagai T
Int Arch Allergy Immunol; 2010; 152(4):407-12. PubMed ID: 20197683
[TBL] [Abstract][Full Text] [Related]
14. del11(p11-13) with overexpression of Wilms' tumor gene during leukemic transformation of myelodysplastic syndrome.
Suzuki S; Hashino S; Yoshida S; Chiba K; Izumiyama K; Kurosawa M; Musashi M; Asaka M
Ann Hematol; 2002 Oct; 81(10):605-8. PubMed ID: 12424545
[TBL] [Abstract][Full Text] [Related]
15. Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia.
Hofmann WK; Heil G; Zander C; Wiebe S; Ottmann OG; Bergmann L; Hoeffken K; Fischer JT; Knuth A; Kolbe K; Schmoll HJ; Langer W; Westerhausen M; Koelbel CB; Hoelzer D; Ganser A
Ann Hematol; 2004 Aug; 83(8):498-503. PubMed ID: 15156346
[TBL] [Abstract][Full Text] [Related]
16. A combination chemotherapy with low doses of cytarabine and etoposide for high risk myelodysplastic syndromes and their leukemic stage. A pilot study.
Kuriya S; Murai K; Miyairi Y; Utsugisawa T; Narigasawa Y; Ito T; Shimosegawa K; Ishida Y
Cancer; 1996 Aug; 78(3):422-6. PubMed ID: 8697386
[TBL] [Abstract][Full Text] [Related]
17. Combination of 5-azacytidine and thalidomide for the treatment of myelodysplastic syndromes and acute myeloid leukemia.
Raza A; Mehdi M; Mumtaz M; Ali F; Lascher S; Galili N
Cancer; 2008 Oct; 113(7):1596-604. PubMed ID: 18720364
[TBL] [Abstract][Full Text] [Related]
18. A case of monocytic leukaemia cutis in a patient with myelodysplastic syndrome transforming to acute myeloid leukaemia.
Perez A; Kennedy C; Standen G; Oxley J
Clin Exp Dermatol; 2004 Sep; 29(5):497-8. PubMed ID: 15347335
[TBL] [Abstract][Full Text] [Related]
19. Intensive chemotherapy for patients with myelodysplastic syndromes and acute myelogenous leukaemia younger than 65 years.
De Witte T; Muus P; De Pauw B; Haanen C
Bone Marrow Transplant; 1989 Dec; 4 Suppl 3():33-5. PubMed ID: 2697396
[TBL] [Abstract][Full Text] [Related]
20. Clinical, hematological and histomorphological profile of myelodysplastic syndrome.
Nigam S; Rani S; Singh T; Gupta S; Rakheja D; Gaiha M
J Assoc Physicians India; 2001 Apr; 49():430-4. PubMed ID: 11762613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
